Market Place
Sourcing Support
CohBar: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
27 Nov 2023 //
BUSINESSWIRE
CohBar Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Morphogenesis and CohBar Announce Positive Results from Ph1b Trial of IFx-Hu2.0
05 Jun 2023 //
GLOBENEWSWIRE
2 small biotechs morph to work on oncology together
23 May 2023 //
FIERCE BIOTECH
CohBar Reports3Q 2022 Financial Results and Highlights Recent Corporate Progress
08 Nov 2022 //
GLOBENEWSWIRE
CohBar to Announce 2022 Third Quarter Financial Results
26 Oct 2022 //
GLOBENEWSWIRE
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
06 Sep 2022 //
GLOBENEWSWIRE
CohBar Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
CohBar to Announce 2022 Second Quarter Financial Results
01 Aug 2022 //
GLOBENEWSWIRE
CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors
12 Jul 2022 //
GLOBENEWSWIRE
CohBar to Participate at Upcoming Conferences in June 2022
07 Jun 2022 //
GLOBENEWSWIRE
CohBar to Present at the H.C. Wainwright Global Investment Conference
19 May 2022 //
GLOBENEWSWIRE
CohBar Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
CohBar Announces Extension of Nasdaq Compliance Period
12 May 2022 //
GLOBENEWSWIRE
CohBar to Announce 2022 First Quarter Financial Results
02 May 2022 //
GLOBENEWSWIRE
CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results
29 Mar 2022 //
GLOBENEWSWIRE
CohBar to Announce 2021 Q4 and FY Financial Results and
15 Mar 2022 //
GLOBENEWSWIRE
CohBar Announces Pricing of $15.0 Million Public Offering
28 Oct 2021 //
GLOBENEWSWIRE
CohBar Announces Proposed Public Offering of Common Stock and Warrants
27 Oct 2021 //
GLOBENEWSWIRE
CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker
13 Oct 2021 //
COHBAR
CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference
05 Oct 2021 //
GLOBENEWSWIRE
CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors
15 Sep 2021 //
GLOBENEWSWIRE
CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for (NASH)
08 Sep 2021 //
BIOSPACE
CohBar Appoints Carol Nast to Its Board of Directors
16 Aug 2021 //
GLOBENEWSWIRE
CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211
14 Jul 2021 //
GLOBENEWSWIRE
CohBar Completes Last Subject Visit in the Phase 1b Trial for CB4211
21 Apr 2021 //
GLOBENEWSWIRE
CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211
29 Mar 2021 //
COHBAR
CohBar, NIAID to assess CB5064 Analogs for Covid-19 treatment
12 Jan 2021 //
PHARMACEUTICAL-TECHNOLOGY
CohBar Antifibrotic Peptide in Combination Nintedanib Shows Enhanced Effects
26 Oct 2020 //
PRESS RELEASE
CohBar Announces Closing of Public Offering of Common Stock and Warrants
28 Aug 2020 //
GLOBENEWSWIRE
CohBar raises $15M in a public offering of common stock and warrants
28 Aug 2020 //
THEFLY
CohBar Announces Proposed Public Offering of Common Stock and Warrants
25 Aug 2020 //
GLOBENEWSWIRE
CohBar Resumes CB4211 Phase 1b Clinical Trial
07 Jul 2020 //
GLOBENEWSWIRE
CohBar’s Abstract for the American Thoracic Society 2020 International Conf.
01 May 2020 //
GLOBENEWSWIRE
CohBar Announces Acceptance of Late Breaking Abstract its Antifibrotic Peptides
14 Apr 2020 //
GLOBENEWSWIRE
